Catalyst Wire Dossier Catalyst Wire Dossier

LQT-1213

· Thryv Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LQT-1213, covering 2025-07-24 to 2025-07-24. Get the full timeline:

Most recent: Clinical Trial Update: Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2). [Phase 1, Phase 2]

See pricing